|
| 33334614 | Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trials. | Vaccine | 2021 |
| 33738316 | A Risk Score to Predict <i>Clostridioides difficile</i> Infection. | Open Forum Infect Dis | 2021 |
| 34483022 | Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years. | Vaccine | 2021 |
| 32766196 | Risk Factors for Primary <i>Clostridium difficile</i> Infection; Results From the Observational Study of Risk Factors for <i>Clostridium difficile</i> Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). | Front Public Health | 2020 |
| 27662551 | Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. | AIDS | 2017 |
| 28140752 | Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants. | Hum Vaccin Immunother | 2017 |
| 27471320 | Human P[6] Rotaviruses From Sub-Saharan Africa and Southeast Asia Are Closely Related to Those of Human P[4] and P[8] Rotaviruses Circulating Worldwide. | J Infect Dis | 2016 |
| 26440913 | Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa. | Sci Rep | 2015 |
| 25424929 | Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects. | Hum Vaccin Immunother | 2014 |
| 23732903 | Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. | Hum Vaccin Immunother | 2013 |
| 21297946 | Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity. | PLoS One | 2011 |
| 19506482 | Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. | J Acquir Immune Defic Syndr | 2009 |
| 18293124 | A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. | AIDS Care | 2008 |
| 16856117 | Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. | Cochrane Database Syst Rev | 2006 |
| 17109338 | A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). | J Infect Dis | 2006 |
| 16951642 | Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. | J Acquir Immune Defic Syndr | 2006 |
| 16856619 | Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. | Antivir Ther | 2006 |
| 16235406 | Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. | Cochrane Database Syst Rev | 2005 |
| 14583845 | A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. | HIV Clin Trials | 2003 |
| 12944569 | Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. | N Engl J Med | 2003 |
| 11018855 | Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. | AIDS Res Hum Retroviruses | 2000 |
| 9841849 | Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. | J Infect Dis | 1999 |
| 10228055 | Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. | J Infect Dis | 1999 |
| 9973442 | Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). | J Immunol | 1999 |
| 10199226 | Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. | AIDS | 1999 |
| 9573309 | Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. | J Virol | 1998 |
| 3531230 | Clinical trial comparing bacitracin with Strep-A-Chek for accuracy and turnaround time in the presumptive identification of Streptococcus pyogenes. | J Clin Microbiol | 1986 |
| 3701541 | Endemic canine and feline histoplasmosis in El Paso, Texas. | J Med Vet Mycol | 1986 |
| 3902878 | Incidence and characterization of beta-hemolytic Streptococcus milleri and differentiation from S. pyogenes (group A), S. equisimilis (group C), and large-colony group G streptococci. | J Clin Microbiol | 1985 |